Fosamax Osteonecrosis of the Jaw Attorney: Statute of Limitations for Fosamax in Illinois

From General Health Awareness to Targeted Risk Evaluation

For decades, the public health landscape has been shaped by broad initiatives aimed at improving general wellness and disseminating accessible information on common medical conditions. This legacy of general health and science communication has built a foundation of awareness around preventive care and the management of chronic diseases. Within this context, certain pharmaceutical interventions have become widely recognized for their role in treating conditions such as osteoporosis, where medications like bisphosphonates have been prescribed to maintain bone density. As the general health narrative evolved, so too did the understanding of potential long-term effects associated with these therapies. In particular, the focus has shifted from general health maintenance to specific, rare but serious adverse events that may arise from prolonged medication use. This transition brings attention to the occupational and environmental dimensions of exposure, especially for individuals who may have been prescribed such treatments in a clinical setting. The concern now extends beyond the patient’s immediate health history to include the circumstances of exposure—namely, the duration and context of medication use. This pivot from general health information to a more targeted inquiry into exposure risk underscores the need for careful consideration of legal and medical timelines, particularly when evaluating potential claims related to adverse outcomes.

Understanding Fosamax and Its Approved Uses

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Osteonecrosis of the Jaw: A Rare but Serious Adverse Event

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, but a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The incidence of ONJ is considered rare, and fragility fracture was not associated with interruption of bisphosphonate prescription for up to two years, after either three or five years of prescription (https://pubmed.ncbi.nlm.nih.gov/42046648/).

Mechanistic Pathways and Warning Adequacy

The mechanistic pathways linking Fosamax to ONJ involve the drug's action on bone remodeling. Bisphosphonates like Fosamax inhibit osteoclast-mediated bone resorption, which can suppress normal bone turnover. In the jaw, which has high bone turnover rates, this suppression may impair the ability to repair microdamage and respond to local infections or dental procedures, leading to necrotic bone exposure. The label notes that ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the Fosamax label includes a specific section on ONJ under "Warnings and Precautions" (5.4) that describes the condition, associated risk factors, and the potential for increased risk with longer exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also advises discontinuation if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the clinical trial data show that the percentage of patients with these symptoms was similar in the Fosamax and placebo groups, suggesting that the absolute risk may be low in the general osteoporosis population (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Statute of Limitations for Fosamax Claims in Illinois

For affected patients in Illinois considering legal action, the statute of limitations is a critical factor. In Illinois, personal injury claims generally must be filed within two years from the date the injury was discovered or should have been discovered through reasonable diligence. For product liability cases involving prescription drugs, the clock may start when the patient knew or should have known that the drug caused the injury. Given that ONJ can develop months after starting Fosamax and may be initially attributed to dental causes, the timeline between exposure and documented harm is variable. Patients should consult with an attorney to determine the applicable deadline based on their specific circumstances. Attorney-related considerations for affected patients include documenting the timeline of Fosamax use, dental procedures, and ONJ diagnosis. Medical records, including dental notes and imaging, are essential to establish the link between the drug and the injury. The label's acknowledgment of ONJ as a known adverse effect supports the argument that the manufacturer was aware of the risk. However, the rarity of the condition and the similarity of symptom rates in clinical trials may be factors in litigation. Patients should also consider whether the warnings provided were adequate for their specific situation, particularly if they underwent dental procedures without being advised of the potential risk.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in Illinois?

In Illinois, personal injury claims generally must be filed within two years from the date the injury was discovered or should have been discovered through reasonable diligence. For product liability cases involving prescription drugs, the clock may start when the patient knew or should have known that the drug caused the injury. Given that ONJ can develop months after starting Fosamax and may be initially attributed to dental causes, the timeline is variable. Patients should consult with an attorney to determine the applicable deadline based on their specific circumstances.

What are the known risk factors for developing ONJ while taking Fosamax?

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How does Fosamax cause osteonecrosis of the jaw?

Fosamax inhibits osteoclast-mediated bone resorption, which can suppress normal bone turnover. In the jaw, which has high bone turnover rates, this suppression may impair the ability to repair microdamage and respond to local infections or dental procedures, leading to necrotic bone exposure. The label notes that ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.